| Analysis | Metabolite Name | Measured Value | Units | Group |
|---|---|---|---|---|
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 0.3916 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 0.5097 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 0.6195 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 0.6308 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 0.6396 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 0.6417 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 0.6489 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 0.6589 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 0.6808 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 0.6812 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 0.7004 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 0.7300 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 0.7499 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 0.7591 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 0.7632 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 0.7878 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 0.7978 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 0.8033 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 0.8074 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 0.8112 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 0.8157 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 0.8191 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 0.8238 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 0.8330 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 0.8392 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 0.8392 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 0.8404 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 0.8454 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 0.8493 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 0.8540 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 0.8634 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 0.8653 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 0.8792 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 0.8811 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 0.8839 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 0.8867 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 0.8871 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 0.8897 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 0.8923 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 0.9088 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 0.9093 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 0.9192 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 0.9195 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 0.9270 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 0.9365 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 0.9377 | Peak area | Normal |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 0.9425 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 0.9426 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 0.9575 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 0.9672 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 0.9822 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 0.9911 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 0.9946 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 1.0054 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 1.0100 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 1.0144 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 1.0260 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 1.0271 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 1.0372 | Peak area | Normal |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 1.0390 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 1.0434 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 1.0514 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 1.0529 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 1.0750 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 1.0854 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 1.0874 | Peak area | Normal |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 1.0891 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 1.0989 | Peak area | Normal |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 1.1003 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 1.1089 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 1.1172 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 1.1214 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 1.1252 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 1.1344 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 1.1554 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 1.1589 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 1.1680 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 1.1743 | Peak area | Normal |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 1.1791 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 1.2086 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 1.2165 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 1.2177 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 1.2181 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 1.2247 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 1.2391 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 1.2463 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 1.2521 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 1.2576 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 1.2736 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 1.2786 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 1.2821 | Peak area | Normal |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 1.2845 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 1.2905 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 1.3127 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 1.3173 | Peak area | Normal |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 1.3369 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 1.3459 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 1.3870 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 1.4329 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 1.4629 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 1.4933 | Peak area | Normal |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 1.5577 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 1.5891 | Peak area | Normal |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 1.6367 | Peak area | Diabetic Neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 1.8098 | Peak area | Diabetic non neuropathy |
| HILIC POSITIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 1.8171 | Peak area | Diabetic Neuropathy |
- UCSD Metabolomics Workbench, a resource sponsored by the Common Fund of the National Institutes of Health
|